Unlock instant, AI-driven research and patent intelligence for your innovation.

Pretargeting kit, method and agents used therein

A kit, pre-targeting technology, used in nuclear imaging and radiotherapy, pre-targeting reagents, pre-targeting kits, non-bioreactive chemical groups, can solve complex chemical problems

Inactive Publication Date: 2012-05-02
KONINK PHILIPS ELECTRONICS NV
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this is often problematic: for example, imaging studies in humans have shown that maximal concentrations of radiolabeled antibodies at tumor sites can be reached within 24 hours, but additional days are required for the labeled antibodies to circulate in the system. The concentration of the antibody drops low enough for successful imaging to occur
[0017] Coupling chemistry of the foregoing type, while useful, requires relatively complex chemistry

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pretargeting kit, method and agents used therein
  • Pretargeting kit, method and agents used therein
  • Pretargeting kit, method and agents used therein

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0119] like Figure 7a Molecule 1 (see Figure 8 ). An example of the corresponding probe 2 (derived from 4-(2-hydroxyethoxy)phenylethylene) is in Figure 9 shown in . Both molecules contain PEG chains. Molecule 1 comprises an N-hydroxysuccinimidyl moiety for coupling the molecule to an amino group present in the antibody. The DOTA-derived moieties in 2 can be used to carry rare earth metal ions such as Gd for MR imaging or Lu-177 for nuclear imaging and therapy (SPECT).

[0120] Figure 8 The synthesis of 1 is shown in . The starting tetrazine-derived molecule 5 was prepared according to Blackman et al. (Blackman, ML; Royzen, M; Fox, JM, Journal of The American Chemical Society, 2008, 130(41), 13518-19). It is converted to acid 6 by reaction with succinic anhydride, followed by its N-hydroxysuccinimidyl ester 7. This N-hydroxysuccinimidyl ester was used to form acid 9 which in turn was converted to its hydroxysuccinimidyl ester 1 by reaction with a commercially availa...

Embodiment 2

[0123] Compared to Example 1, this example illustrates the opposite molecular pair, namely 1) a 4-(2-hydroxy)ethoxy)phenylethylene derivative that will form the pre-targeting moiety after attachment to the antibody 3 and, 2) Probe 4 derived from said tetrazine / DOTA, which can be used as Figure 7b Effector probes shown in , respectively, in Figure 10 and 11 shown in .

[0124] Commercially available (IRIS biochem) PEG derivative 8 with N-hydroxysuccinimidyl ester 14 (see Figure 9 ) to form acid 19, followed by the formation of N-hydroxysuccinimidyl derivatives derived from this acid to form 4-(2-hydroxy)ethoxy)phenylethylene derivatives 3.

[0125] The synthesis of probe 4 derived from tetrazine / DOTA is shown in FIG. 7 . By amine 18 derived from DOTA and PEG (see Figure 9 ) and N-hydroxysuccinimidyl ester 7 (see Figure 8 ) reaction to prepare this probe.

Embodiment 3

[0126] Example 3: In Vivo Imaging

[0127] All reagents and solvents were obtained from commercial sources (reagents from Sigma-Aldrich, Acros, ABCR, Invitrogen, and Merck, conventional and deuterated solvents from Biosolve, Merck, and Cambridge Isotope Laboratories) and were not further prepared unless otherwise stated. The purification is ready to use. 1-Amino-3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36-dodeoxanonacosane-39-oic acid (S11) and (35-amino-3 , 6, 9, 12, 15, 18, 21, 24, 27, 30, 33-tert-butyl carbamate (S3) from Polypure (Norway) and Iris Biotech (Germany )get. 2,2',2"-(10-(2-((2,5-dioxopyrrolidin-1-yl)oxy)-2-oxoethyl)-1,4,7,10- Tetraazacyclododecane-1,4,7-triyl)triacetic acid (S6) as the HPF 6 and about 3 equivalents of trifluoroacetic acid (TFA) were obtained from Macrocyclics (USA). Rituximab solution (MabThera ) were purchased from Roche (Switzerland). [ 111 In] indium chloride and [ 125 I] Sodium iodide solution was purchased from PerkinElmer (USA...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
purityaaaaaaaaaa
Login to View More

Abstract

Described is a pretargeting method, and related kits, for targeted medical imaging and / or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other an alkene or alkyne dienohile.

Description

technical field [0001] The present invention relates to a pretargeting method for targeted medical imaging and / or therapy using abiotic reactive chemical groups that exhibit bio-orthogonal reactivity with each other . The present invention also relates to a pre-targeting kit (kit) containing at least one pre-targeting probe and at least one effector probe, wherein the pre-targeting probe comprises A primary targeting moiety and a first bioorthogonal reactive group, and wherein the effector probe comprises an effector moiety, such as a label or a pharmaceutically active compound, and a second bioorthogonal reactive group. The present invention also relates to pre-targeting reagents for use in the above methods and kits. The invention particularly relates to nuclear imaging and radiation therapy. Background technique [0002] In many areas of medical diagnosis and treatment, it is desirable to selectively deliver agents, such as therapeutic (drugs) or diagnostic (eg imaging...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/48A61K51/04A61K51/10
CPCA61K51/0495A61K47/48746B82Y5/00A61K51/1027A61K51/1045A61K47/6897
Inventor M·S·罗比拉尔德R·罗辛J·卢布P·雷纳特弗柯克D·伯丁斯基
Owner KONINK PHILIPS ELECTRONICS NV